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Abstract
Background: It has been hypothesized that alterations of the serotonergic system contribute to
neuropsychiatric symptoms in Alzheimer disease (AD). Cellular expressions of the two
serotonergic receptors 5-HT2A  and 5-HT6  have therefore been determined by
immunohistochemistry in the prefrontal cortex of patients with AD (n=6) and normal age-matched
controls (n = 7).
Results: In normal aging patients, 5-HT2A label was mainly observed in large pyramidal cells, but to
a lesser extent also in small pyramidal cells and in stellate cells of cortical layers II-VI. In AD, a
similar distribution was observed, but density of positive cells was significantly reduced by 33%. In
aging control patients, the 5-HT6 receptor was expressed by pyramidal cells and occasional stellate
cells, not only of layers II-V, but also of layer I, where a distinct label was observed in neurons and
surrounding fibers. 5-HT6 receptor expression in AD patients had the same pattern, but was
significantly decreased by 40%.
Conclusion: Our results indicate that a decline in neurons expressing 5-HT2A, but also 5-HT6
receptors may play a role in the etiopathology of neuropsychiatric symptoms in AD.
Background
Alzheimer disease (AD), the most common cause of
dementia in the elderly, is clinically characterized by pro-
gressive cognitive impairment associated with severe neu-
ropsychiatric disturbances. These behavioral and
psychological symptoms of dementia (BPSD) include hal-
lucinations, delusions, aggressive behavior, overactivity,
anxieties and affective disturbances [1,2]. Whereas the
decline in cognitive functions can be largely related to
cholinergic dysfunction arising from disruption of basal
forebrain cholinergic pathways (cholinergic hypothesis)
[1,3,4], impaired balance between several neurotransmit-
ters has been implicated in the pathogenesis of BPSP [2,5-
7], with serotonin (5-HT) playing a pivotal role [2,8-10].
The actions of 5-HT are mediated through seven major
receptors classes, 5-HT1–7, comprising a total of 14 distinct
mammalian 5-HT receptor subtypes (for review, see [11]).
The 5-HT2A receptor has attracted most interest because of
its possible participation in behavioral alterations in AD.
5-HT2A  is localized in the cortex and caudate and is
involved in anxiety [10]. 5-HT2A receptors mediate the
psychotomimetic effects of hallucinogens [11-13], and
alterations in binding characteristics to this receptor have
been observed in the prefrontal cortex of patients suffer-
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ing from psychiatric diseases, e.g. schizophrenia [14,15],
depression [16] and suicide [17]. Electrophysiological evi-
dence suggests that 5-HT2A receptors are involved in the 5-
HT-induced increase in excitatory postsynaptic potentials
[12,18] and play an important role in the working mem-
ory process [13]. There is indication that 5-HT2A also par-
ticipates in the etiopathology of AD. Serotonin increases
the secretion of amyloid precursor protein (APP) through
activation of 5-HT2A receptors [19]. 5-HT2A receptor bind-
ing is decreased in AD (for review, see [9,10]), and poly-
morphic variations have been described for the 5-HT2A
gene that may be risk factors for hallucinations [20],
aggression [21] and major depression [22] in AD. Much
less is known about the 5-HT6 receptor, the most recent 5-
HT receptor to be identified. Many antidepressants and
antipsychotics are antagonists of the 5-HT6  receptor
[15,23]. It has been shown to influence acetylcholine
release in the frontal cortex [24] and may play a role in
cognition deficits and in some form of anxiety [23]. A
recent autoradiographic study examining [125I]-SB-
258585 binding in autopsy specimens of AD patients
indicates lowered 5-HT6 receptor density in the frontal
and temporal cortices [5]. Association of a 5-HT6 receptor
gene polymorphic variant and late-onset AD has been
observed in the Chinese population [25], but not in Ger-
mans [26].
Surprisingly, although 5-HT2A and 5-HT6 receptor bind-
ing in AD has been studied extensively [2,5,9,10], there is
no information on the expression of these receptors at the
cellular level. We have therefore examined the expression
of the 5-HT2A and 5-HT6 receptors in the brains of AD and
of normal aging control patients by immunohistochemis-
try. Because the prefrontal cortex is of particular impor-
tance for the etiopathology of BPSD [1,8,12,14,16,27-31]
and because neuropsychiatric symptoms in AD are associ-
ated with reduced metabolism [32,33] and perfusion [34]
in Brodmann area 10, we have chosen this brain region
for examination.
Methods
Tissue samples
The brains were obtained from a total of 13 autopsy cases
with the consent of a close relative and with full approval
by the ethical committees of Guangzhou hospital author-
ities and of the Chinese University of Hong Kong. Six of
the specimens were from individuals with clinically and
pathologically diagnosed senile dementia of the Alzhe-
imer's type (mean age: 88 years, see table 1), seven speci-
mens were from individuals, matched for age, gender and
postmortem delay, who had no history of neurological dis-
eases (normal control). Drug history was recorded for all
patients, who had only received antibiotic treatment, but
no psychopharmacological medication. Alzheimer Dis-
ease was clinically diagnosed according to the "National
Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer's Disease and Related Dis-
orders Association" (NINCDS-ADRA) criteria and the
"Diagnostic and Statistical Manual of Mental Disorders",
Fourth Edition, (DSM-IV-R) criteria.
Whole brains were removed with an average postmortem
delay of six hours, and tissue samples of the anterior pre-
frontal cortex (Brodmann's area 10) were dissected. Spec-
imens were fixed overnight in 4% paraformaldehyde in
phosphate-buffered saline (PBS; ph 7.4), dehydrated in
graded ethanol, cleared with xylene and embedded in par-
affin. 6-μm-thick serial sections were cut in the coronal
plane, 90° perpendicular to the surface to avoid section-
ing artifacts. Two sets of slides were obtained for each
individual.
Immunohistochemistry
All steps were carried out at room temperature unless
stated otherwise. Mounted sections were dewaxed, rehy-
Table 1: Profiles of Alzheimer (AD) and matched normal aging patients
Subject Diagnosis Sex Age Cause of death
1 Normal F 83 Pneumonia
2 Normal F 86 Gastrointestinal bleeding
3 Normal M 82 Pneumonia
4 Normal M 93 Sudden death
5 Normal F 72 Sudden death
6 Normal F 85 Pneumonia
7 Normal F 81 Pneumonia
8 Alzheimer M 82 Subarachnoid hemorrhage
9 Alzheimer F 91 Septicemia
10 Alzheimer F 96 Pneumonia
11 Alzheimer F 82 Pneumonia
12 Alzheimer F 86 Pneumonia
13 Alzheimer F 89 Sudden deathBMC Neuroscience 2006, 7:36 http://www.biomedcentral.com/1471-2202/7/36
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drated and predigested with 0.1% trypsin (BDH Labora-
tory Supplies, Poole, U.K.) in 0.05M tris buffered saline
containing 0.1% CaCl2 (pH 7.6; 37°C; 20 min) followed
by two rinses (5 min) in 0.01M PBS for antigen retrieval.
The endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide in absolute methanol for 30
min, followed by another three rinses in PBS (5 min
each). To suppress non-specific binding, sections were
then incubated for 1h in 2 % normal blocking serum
(VectastainR ABC Kit, Vector Laboratories, Burlingame,
CA) in 0.3 % triton/PBS. Thereafter, sections were incu-
bated overnight with the primary polyclonal antibodies:
either goat anti-human serotonin 2A receptor (Santa Cruz
sc-15073, Santa Cruz Biotechnology Inc., Sta. Cruz, CA)
or goat anti-human serotonin 6 receptor (Santa Cruz sc-
26668). The sections were then washed with three rinses
of PBS containing 0.05 % Tween 20 (5 min each) and
incubated with biotinylated secondary antibody in block-
ing solution (1:200) for 30 min (PK6105, anti-goat IgG,
VectastainR  ABC Kit, Vector Laboratories, Burlingame,
CA). Sections were washed three times in PBS again (5
min) and incubated with ABC Reagent (VectastainR ABC
Kit, Vector Laboratories, Burlingame, CA) for 30 min. The
immunocytochemical staining signals were visualized by
incubating the sections in 0.05% of the substrate 3'3'-
diaminobenzidine tetrahydrochloride (DAB) in PBS con-
taining 0.01% H2O2. All stainings included negative con-
trols with omission of the primary antibody, which did
not show any immunoreaction. The sections were washed
with distilled water and then counterstained with 0.5%
cresyl fast violet in 0.1M sodium acetate (pH 3.5, 5 min).
They were differentiated with 95% ethanol, dehydrated,
cleared and covered in Permount®  (Fisher Scientific,
Hampton, VA). Additional sections were stained with rou-
tine methods, including H&E, Nissl and Bielschowsky sil-
ver impregnation for tangle staging [35,36].
All cases underwent a standardized post-mortem neu-
ropathological assessment of AD using established criteria
including Braak staging [35]. Four brain regions were
examined: prefrontal (area 10), occipital (area 17),
entorhinal (area 28) and hippocampal cortices. Diagnosis
was confirmed by the characteristic presence of amyloid
plaques, neurofibrillary tangles (NFT) and neuronal
degeneration. In addition, the presence of β-amyloid in
the plaques was ascertained by immunohistochemistry
using the rabbit polyclonal Anti-Amyloid Peptide β,
Cleavage site 42 (Aβ42), antibody (A1976, Sigma, St.
Louis, MU) [37]. All AD cases had neocortical NFT with
involvement of both isocortical association areas and
additional involvement of primary cortical (area 17) areas
(Braak stage V-VI). In control patients, deposition of NFT
was negligible in the entorhinal cortex and absent in the
hippocampus as well as the neocortex (Braak stage = I). To
exclude Dementia with Lewy bodies, all brain specimens
were scrutinized for Lewy bodies, and only cases devoid of
Lewy bodies were included in the study.
Statistics
For qualitative and quantitative evaluation, sections were
observed under a photomicroscope (Axioplan 2 Photom-
icroscope, Zeiss, Germany). The number of 5-HT2A- and 5-
HT6-immunoreactive cells was counted in 30 random
selected 700 μm2 fields of normal aged and AD patients.
4–5 sections per individual were evaluated, sparing areas
containing amyloid plaques. It has been shown in AD
patients [38] that astrocytes in and around Aβ plaques are
strongly positive for 5-HT2A  receptor protein, whereas
astrocytes in control patients do not display any 5-HT2A
immunoreaction. Amyloid plaques were therefore
excluded from the quantitative assessment, because the
aim of our study was to count neurons expressing 5-HT
receptors. Measurements were expressed as means ± SEM.
For statistical comparison, the values were subjected to a
one-way analysis of variance (ANOVA), demonstrating
that the four data groups exhibited equal variance, but
were not distributed normally. We have then applied the
One Way non-parametric ANOVA (Kruskal-Wallis test)
and the Mann Whitney Rank sum test, yielding the same
results. A p value below 0.05 was considered significant.
Results
In the prefrontal cortex of normal aging patients, 5-HT2A
receptor immunoreaction was observed in cortical layers
II-VI. Large pyramidal neurons of layer V constituted the
majority of immunoreactive cells, characterized by a
strongly labeled cytoplasm and a moderately stained
proximal part of the apical dendrite (Figs. 1a, c). In addi-
tion, smaller pyramidal cells and scattered stellate-shaped
cells in the other layers were immunoreactive. Stellate
cells had a strongly stained cytoplasm and labeled thin
processes radiating to the side of the ovoid cell bodies and
most likely represented interneurons. A few multipolar
cells in layer VI were also 5-HT2A receptor positive. In the
underlying white matter, occasional 5-HT2A  receptor
immunoreactive fiber bundles were observed. AD patients
showed a similar distribution of 5-HT2A receptor label in
the prefrontal cortex, i.e. staining in the cell bodies and
apical dendrites of large pyramidal cells and in the soma
and tender processes of a few scattered interneurons (Figs.
1b, d). However, numerical density of 5-HT2A receptor
immunoreactive cells was significantly (p=0.001)
decreased by 33% in the frontal cortex of AD patients (Fig.
2), as compared to normal aging patients. Reduction
affected both pyramidal cells and cells of stellate mor-
phology. In addition, labeled cells were also seen within
and close to amyloid plaques. An association between 5-
HT2A receptors and NFT was not observed.BMC Neuroscience 2006, 7:36 http://www.biomedcentral.com/1471-2202/7/36
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5-HT2A receptor Figure 1
5-HT2A receptor. Immunoreaction for the 5-HT2A receptor in the prefrontal cortex of a normal aging (a, c) and an Alzheimer 
patient (b, d), cresyl violet counterstain. Both large pyramidal cells (arrowheads) and small interneurons (arrows) are stained. 
Note the reduction in labeled cells in the cortex of the Alzheimer patient (b, d). a, b: x200; c, d; x400.BMC Neuroscience 2006, 7:36 http://www.biomedcentral.com/1471-2202/7/36
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Distribution of 5-HT6 receptor immunoreaction in the
prefrontal cortex of normal aging patients was slightly dif-
ferent from that of the 5-HT2A receptor. As for the 5-HT2A
receptor, the most prominent label was observed in the
cell bodies and the proximal apical dendrites of large
pyramidal neurons, and occasionally, the soma and fine
processes of scattered stellate cells were stained as well
(Figs. 3a, c). In addition, 5-HT6 receptor immunoreaction
was also detected in neurons of the molecular layer (layer
I). These cells had a bipolar strongly labeled cell body and
numerous immunoreactive processes radiating into the
molecular layer (Fig. 3d). In contrast, hardly any 5-HT6
receptor immunoreactive cells were observed in layer VI.
Occasional immunoreactive fiber bundles were seen in
the underlying white matter. In summary, density of 5-
HT6 receptor positive neurons was significantly higher
than that of 5-HT2A  receptor immunoreactive cells
(p=0.05). In the prefrontal cortex of AD patients, 5-HT6
receptor label showed the same overall distribution (Figs.
3b, e), but numerical density of 5-HT6 receptor immuno-
reactive cells was again significantly (p=0.001) reduced, as
compared to normal aging patients (Fig. 2). Both pyrami-
dal and stellate cells were decreased by about 40%. There
was no association between 5-HT6 receptors and NFT.
Discussion
The present study has been undertaken in order to deter-
mine changes in cellular distribution of two serotonin
receptors, 5-HT2A and 5-HT6, in the prefrontal cortex of
AD patients as compared to normal age-matched individ-
uals. Our observation in aging (control) patients, showing
5-HT2A immunoreactivity in the cell bodies and the apical
dendrites of pyramidal cells as well as in stellate-shaped
cells, is consistent with previous studies in young humans
[17], primates [18,39] and rodents [40,41]. However, we
have detected relatively few labeled cells, and we are cur-
rently testing if the paucity in 5-HT2A receptors is attribut-
able to the very advanced age of our patients or to the
technique employed. A considerable age-related reduc-
tion in the number of cortical 5-HT2A binding sites in the
frontal lobe has been described by numerous authors (see
[9] for review). In contrast to 5-HT2A, relatively little is
known on the distribution of the 5-HT6 receptor in the
mammalian neocortex. 5-HT6 receptor binding sites have
been detected by receptor autoradiography in the gray
matter of the prefrontal cortex of healthy human adults
[5,42], but there are no studies on the cellular level. We
have been able to show that the 5-HT6  receptor is
expressed both by pyramidal cells and by stellate-shaped
cells located in cortical layers I-V. We have observed very
little 5-HT6 immunoreaction in layer VI, but a distinct 5-
HT6 label in layer I, with staining detected not only in a
dense network of fibers, but also in neurons. This is some-
what at variance with a study on the rat neocortex, where
5-HT6 receptor mRNA has been detected by in-situ hybrid-
ization in layers II-VI, but not in layer I [43]. This discrep-
ancy is, however, not surprising, given the marked inter-
species differences described [44].
To our knowledge, this is the first immunohistochemical
study of 5-HT2A receptor expression in AD. The reduction
observed corroborates the results of previous 5-HT2A
receptor binding studies showing decreased binding of 3
[H] ketanserin [45-47] and 3 [H] spiperone [48] in post-
mortem specimens of the frontal cortex of AD patients and
in PET imaging studies [49]. Contrasting reports describ-
ing unaltered 3 [H] ketanserin binding [50], which are at
variance with our results, may be attributable to recent
psychotropic medication, which had not been adminis-
tered to our patients. Reduced 5-HT2A receptor binding in
AD has been explained by a loss of interneurons [51]. In
contrast, our immunohistochemical data indicate that
both 5-HT2A  immunoreactive pyramidal and stellate-
shaped cells, i.e. interneurons, are affected in AD. Moreo-
ver, we have demonstrated that the density of neurons
expressing the 5-HT6  receptor is reduced to a similar
extent, corroborating autoradiographic studies revealing
decreased binding to 5-HT6 receptors in the prefrontal cor-
tex of AD patients [5]. Our observation of reduced density
of neurons expressing 5-HT2A and 5-HT6 receptors, which
is not accompanied by similar alterations in GABAergic
markers [6], points at a selective vulnerability of neurons
receiving serotonergic input. This decrease is associated
with several other abnormalities of the serotonergic sys-
tem in AD. A marked depletion in 5-HT and its metabolite
5-Hydroxyindole Acetic Acid (5-HIAA) has been
Cell densities Figure 2
Cell densities. Numerical density of 5-HT2A and 5-HT6 
receptor immunoreactive neurons in the prefrontal cortex of 
normal aging (n=7) and Alzheimer (AD) patients (n=6). 
Depicted are means ± SEM. Significant differences (p ≤ 0.05) 
are marked by an asterisk (*)BMC Neuroscience 2006, 7:36 http://www.biomedcentral.com/1471-2202/7/36
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described in the frontal and temporal cortices of AD
patients [2,28,52], which is most likely attributable to a
reduction in serotonergic projection fibers. The underly-
ing cause appears to be a significant loss of neurons in the
dorsal and median raphe nuclei [53,54], which are the
source of serotonergic nerve terminals and which, in addi-
tion, are a preferential site for neurofibrillary tangle for-
mation [55]. It is very likely that the decrease in neurons
expressing 5-HT2A and 5-HT6 receptors is related to this
loss of serotonergic fibers. However, it may either reflect a
process of primary cortical degeneration [4,56] leading to
presynaptic disturbance of the serotonergic system, or be
secondary to the decrease in serotonergic afferents.
Several lines of evidence indicate that serotonergic dys-
function in AD has important functional consequences.
In a study using retrospective data, loss in 5-HT2A binding
has been confined to AD patients with aggressive symp-
5-HT6 receptor Figure 3
5-HT6 receptor. 5-HT6 receptor immunoreactive cells in the prefrontal cortex of normal aging (a, c, d) and Alzheimer 
patients (b, e), cresyl violet counterstain. Label is observed in large pyramidal cells (arrowhead) and small interneurons (arrow). 
Note positive cells and dense immunoreactive fibers in the molecular layer (d). In the cortex of the Alzheimer patient (b, e), 
significantly fewer cells are labeled than in that of the normal aging patient (a, c, d). a, b: x200; c, d, e; x400.BMC Neuroscience 2006, 7:36 http://www.biomedcentral.com/1471-2202/7/36
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toms [57]. When cognitive function is assessed antemor-
tem, 5-HT2A receptors are lost in the frontal and temporal
cortex only in patients with severe, but not with mild to
moderate dementia [47]. The decrease in the expression of
5-HT6 receptors in the prefrontal cortex of AD patients can
be correlated to the extent of aggressive behavior [5]. The
number of 5-HT uptake sites is significantly reduced in the
frontal and temporal cortex of AD patients with persistent
depression, anxiety and overactivity, compared with AD
patients without these symptoms [52], and 5-HT levels in
the prefrontal cortex (Brodmann 10) of AD correlate with
overactivity [2].
Conclusion
Our results of normal aging patients, showing that 5-HT2A
and 5-HT6 receptors are expressed by both pyramidal cells
and stellate-shaped neurons, indicate that serotonergic
fibers exert their influence upon these two neocortical cell
types not only through the 5-HT2A, but also the 5-HT6
receptor. The significant 33–40% reduction in cells
immunoreactive for 5-HT2A and 5-HT6 receptors observed
in AD patients, affecting both large pyramidal cells and
interneurons, points at a severely compromised seroton-
ergic system in AD, involving not only serotonergic pro-
jection fibers, but also their corresponding receptors. This
decline in receptors most likely contributes to the devel-
opment of neuropsychiatric symptoms in AD.
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